Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 3/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22498044 | 1.00 | P2RY14 (0.41) | P2RY14NOTUMMRGPRX4RXRARXRB | |
| SCHEMBL29659839 | 0.87 | NOTUM (0.56) | NOTUMMRGPRX4CES2HIF1A | |
| SCHEMBL22497949 | 0.87 | NOTUM (0.56) | NOTUMMRGPRX4CES2HIF1A | |
| SCHEMBL21609776 | 0.80 | CCR2 (0.45) | P2RY14NOTUMMRGPRX4RXRARXRB | |
| SCHEMBL21609797 | 0.77 | CES2 (0.43) | P2RY14MRGPRX4RXRARXRBRXRG | |
| SCHEMBL24454293 | 0.76 | HDAC3 (0.40) | NOTUMOPRM1 | |
| SCHEMBL29659847 | 0.75 | NOTUM (0.44) | NOTUM | |
| SCHEMBL23113569 | 0.75 | TSHR (0.35) | — | |
| SCHEMBL22497913 | 0.75 | NOTUM (0.44) | NOTUM | |
| SCHEMBL24526956 | 0.75 | HCAR1 (0.42) | PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527325-B2 | Pesticidally active diazine-amide compounds | SYNGENTA CROP PROTECTION AG (CH) | 2026-01-20 | — | — | US | disclosed |
| CN-113661165-B | Pesticidally active diazine-amide compounds | 先正达农作物保护股份公司 | 2025-05-23 | — | — | CN | disclosed |
| US-12281095-B2 | Pesticidally active diazine-amide compounds | SYNGENTA CROP PROTECTION AG (CH) | 2025-04-22 | — | — | US | disclosed |
| CN-113631549-B | Pesticidally active diazine-amide compounds | 先正达农作物保护股份公司 | 2025-01-17 | — | — | CN | disclosed |
| US-20220185789-A1 | PESTICIDALLY ACTIVE DIAZINE-AMIDE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2022-06-16 | — | — | US | disclosed |
| US-20220159958-A1 | PESTICIDALLY ACTIVE DIAZINE-AMIDE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527325-B2 | Pesticidally active diazine-amide compounds | DDT, CHRM1, C3AR1 | P2RY14 3867/4885NOTUM 302/4885MRGPRX4 2586/4885 |
| US-20220185789-A1 | PESTICIDALLY ACTIVE DIAZINE-AMIDE COMPOUNDS | DDT, ACHE, NIT2 | P2RY14 2369/4885NOTUM 236/4885MRGPRX4 4075/4885 |
| US-12281095-B2 | Pesticidally active diazine-amide compounds | DDT, ACHE, NIT2 | P2RY14 2369/4885NOTUM 236/4885MRGPRX4 4075/4885 |
| US-20220159958-A1 | PESTICIDALLY ACTIVE DIAZINE-AMIDE COMPOUNDS | DDT, ACHE, NIT2 | P2RY14 2134/4885NOTUM 160/4885MRGPRX4 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.